Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation

Bone Marrow Transplantation

Volumn 32, Issue 7, 2003, Pages 703-707

  Vij, R ^a   Khoury, H ^a   Brown, R ^a   Goodnough, L T ^a   Devine, S M ^a   Blum, W ^a   Adkins, D ^a   DiPersio, J F ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allo PBSC transplant; Cytomegalovirus; Ganciclovir; Pre emptive therapy

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FOSCARNET; GANCICLOVIR; GROWTH FACTOR; PREDNISONE;

ADOLESCENT; ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; COHORT ANALYSIS; COLITIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DONOR; DRUG COST; DRUG TOLERABILITY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL; PNEUMONIA; PRIORITY JOURNAL; RECIPIENT; SHORT COURSE THERAPY; SIBLING; STEM CELL TRANSPLANTATION; VIREMIA; VIRUS CULTURE;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; INCIDENCE; MIDDLE AGED; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; SIBLINGS; TRANSPLANTATION, HOMOLOGOUS; VIREMIA;

EID: 0141996943     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704216     Document Type: Article

References (29)

1. Bowden RA, Slichter SJ, Sayers MH et al. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991; 78: 246-250.
2. Miller WJ, McCullough J, Balfour HH et al. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant 1991; 7: 227-234.
3. Winston DJ, Ho WG, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 1993; 118: 179-184.
4. Goodrich JM, Bowden RA, Fisher L et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173-178.
5. Salzberger B, Bowden RA, Hackman RC et al. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood 1997; 90: 2502-2508.
6. Goodrich JM, Mori M, Gleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325: 1601-1607.
7. Schmidt GM, Horak DA, Niland JC et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med 1991; 324: 1005-1011.
8. Singhal S, Mehta J, Powles R. Prevention of cytomegalovirus disease by a short course of preemptive ganciclovir or foscarnet. Blood 1994; 84: 2055.
9. Peggs KS, Preiser W, Kottaridis PD et al. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation. Br J Haematol 2000; 111: 782-790.
10. Reusser P, Einsele H, Lee J et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002; 99: 1159-1164.
11. Einsele H, Ehninger G, Hebart H et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815-2820.
12. Machado CM, Menezes RX, Macedo MC et al. Extended antigenemia surveillance and late cytomegalovirus infection after allogeneic BMT. Bone Marrow Transplant 2001; 28: 1053-1059.
13. Mori T, Okamoto S, Matsuoka S et al. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 25: 765-769.
14. Kanda Y, Mineishi S, Saito T et al. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan. Bone Marrow Transplant 2001; 27: 437-444.
15. Nichols WG, Corey L, Gooley T et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 2001; 97: 867-874.
16. Moretti S, Zikos P, VanLint MT et al. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study. Bone Marrow Transplant 1998; 22: 175-180.
17. Boeckh M, Gooley TA, Myerson D et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063-4071.
18. Sakuma H, Hosoya M, Kanno H et al. Risk of cytomegalovirus infection after peripheral blood stem cell transplantation. Bone Marrow Transplant 1997; 19: 49-53.
19. Trenschel R, Ross S, Husing J et al. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT. Bone Marrow Transplant 2000; 25: 665-672.
20. Manteiga R, Martino R, Sureda A et al. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience. Bone Marrow Transplant 1998; 22: 899-904.
21. Link H, Arseniev L, Ljungman P et al. Cytomegalovirus infections after allogeneic peripheral blood progenitor cell transplantation (PBSCT) - a survey of the infectious disease working party of EBMT. Blood 1997; 90(Suppl. 1): 544a (Abstr. 2424).
22. Gleaves CA, Smith TF, Shuster EA et al. Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen. J Clin Microbiol 1984; 19: 917-919.
23. Swenson PD, Kaplan MH. Rapid detection of cytomegalovirus in cell culture by indirect immunoperoxidase staining with monoclonal antibody to an early nuclear antigen. J Clin Microbiol 1985; 21: 669-673.
24. Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
25. Vij R, DiPersio J, Venkatraman P et al. Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation. Blood 2003; 101: 2067-2069.
26. Meyers JD, Flournoy N, Thomas ED et al. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478-488.
27. Storch GA, Buller RS, Bailey TC et al. Comparison of PCR and pp65 antigenemia assay with quantitative shell vial culture for detection of cytomegalovirus in blood leukocytes from solid-organ transplant recipients. J Clin Microbiol 1994; 32: 997-1003.
28. Brown RA, Adkins D, Khoury H et al. Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: graft-versus-host disease and transplant-related mortality. J Clin Oncol 1999; 17: 806-812.
29. Korbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.